Rossana Corbo

Rio De Janeiro, RJ, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Is peptide receptor radionuclide therapy still a promising option for medullary thyroid carcinoma?

Is peptide receptor radionuclide therapy still a promising option for medullary thyroid carcinoma?

Journal: Endocrine

Published: October 05, 2024

Radioiodine treatment in female survivors of pediatric differentiated thyroid carcinoma does not affect future pregnancy rates.

Radioiodine treatment in female survivors of pediatric differentiated thyroid carcinoma does not affect future pregnancy rates.

Journal: Archives of endocrinology and metabolism

Published: January 26, 2024

External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long-term local disease control?

External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long-term local disease control?

Journal: Head & neck

Published: December 30, 2023

Serum anti-Müllerian hormone is lower in patients with multiple radioiodine dose for treatment of pediatric thyroid cancer.

Serum anti-Müllerian hormone is lower in patients with multiple radioiodine dose for treatment of pediatric thyroid cancer.

Journal: European thyroid journal

Published: December 04, 2023

Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients.

Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients.

Journal: Endocrine

Published: October 11, 2023

Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients.

Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients.

Journal: Endocrine

Published: December 12, 2022

An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study.

An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study.

Journal: Thyroid : official journal of the American Thyroid Association

Published: October 12, 2022

Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients.

Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients.

Journal: Endocrine

Published: April 25, 2022

Clinical decision support analysis of a microRNA-based thyroid molecular classifier: A real-world, prospective and multicentre validation study.

Clinical decision support analysis of a microRNA-based thyroid molecular classifier: A real-world, prospective and multicentre validation study.

Journal: EBioMedicine

Published: February 21, 2022

Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis?

Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis?

Journal: European thyroid journal

Published: January 11, 2022

Pregnancy has no significant impact on the prognosis of differentiated thyroid cancer.

Pregnancy has no significant impact on the prognosis of differentiated thyroid cancer.

Journal: Archives of endocrinology and metabolism

Published: November 11, 2021

Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence.

Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence.

Journal: Frontiers in nuclear medicine

Published: September 29, 2021

Showing 1-12 of 39

Last Updated: 09/26/2026